OCT 10, 2017 9:00 AM PDT

WEBINAR: Automated single cell dissociation of primary tumors and patient-derived xenografts

Sponsored by: Miltenyi Biotec
Speaker
  • Assistant Laboratory Member, Memorial Sloan Kettering Cancer Center Medicine
    Biography
      My lab focuses on development of new patient derived xenograft models and experimental lung cancer therapeutics. During my career I have developed a wide range of skills in both laboratory based and computational research. My hybrid skill set positions me well to operate at the interface between the world of the wet lab and that of the high-performance computing cluster. My research has focused on the genetic and epigenetic landscapes of small cell lung cancer, therapeutic targeting of the DLL3, and development of oncolytic viral therapies. In addition to my primary research focus, I established and currently oversee an active program in patient-derived xenograft development and characterization. Through this program I have developed a series of best practices for genetic characterization of human xenografts grown in mice and biomarker validation in PDX.

    Abstract

    DATE: October 10, 2017
    TIME: 9:00AM PDT

    Patient-derived xenografts (PDX) are increasingly being used in biomedical research for therapeutic analysis in mice. Unlike traditional cell line xenografts, which are established from suspensions of cultured cells, PDX are maintained entirely in vivo. While exclusive in vivo maintenance is the primary advantage of PDX as a model for cancer, the practice introduces unique challenges and potential pitfalls to working with PDX as a model for cancer. Perhaps the most significant challenge to working with PDX is the need to disaggregate solid tumors prior to their use in downstream applications such as flow cytometry, immunomagnetic enrichment, single-cell sequencing or the establishment of cohorts for therapeutic trials. This webinar will discuss our experience with automated single cell dissociation of primary tumors and patient-derived xenografts as well as compatibility with downstream applications.

     

    Learning Objectives:

    • Advantages and challenges associate with using PDX models for cancer research
    • Solid tumor dissociation methods compatible for downstream single-cell applications, such as flow cytometry, immunomagnetic enrichment and single-cell sequencing

    Show Resources
    You May Also Like
    DEC 02, 2020 8:00 AM PST
    C.E. CREDITS
    DEC 02, 2020 8:00 AM PST
    DATE: December 2nd, 2020 TIME: 08:00am PDT, 11:00pm EDT Bioreactors and shakers are used to cultivate microorganisms, plant, insect, and mammalian cells in different volumes. Upscaling of pr...
    OCT 08, 2020 7:00 AM PDT
    C.E. CREDITS
    OCT 08, 2020 7:00 AM PDT
    DATE: October 8, 2020 TIME: 7:00am PDT, 10:00am EDT, 4:00pm CEST How often do you pipette in your cell culture lab every day? Usually, we do it so often that we tend stop thinking about ho...
    SEP 10, 2020 9:00 AM PDT
    C.E. CREDITS
    SEP 10, 2020 9:00 AM PDT
    Date: September 10, 2020 Time: 9:00am (PDT), 12:00pm (EDT) Osmolality testing is relevant throughout the entire bioprocessing workflow. As customers look to refine mAb and gene therapy workf...
    AUG 25, 2020 8:00 AM PDT
    C.E. CREDITS
    AUG 25, 2020 8:00 AM PDT
    DATE: August 25, 2020 TIME: 8:00am PDT, 10:00am CDT, 11:00am EDT Recombinant lentivirus (LV) and adeno-associated virus (AAV) are critical components of cell and gene therapies, which show g...
    NOV 16, 2020 8:00 AM PST
    C.E. CREDITS
    NOV 16, 2020 8:00 AM PST
    Date: November 16, 2020 Time: 8:00am (PST), 11:00am (EST) CRISPR screening has become the prime discovery tool in modern biomedical research and drug discovery. At the same time, most screen...
    OCT 29, 2020 6:00 AM PDT
    C.E. CREDITS
    OCT 29, 2020 6:00 AM PDT
    Date: October 29, 2020 Time: 6:00am (PDT), 9:00am (EDT), Chronic inflammation can occur as a result of a combination of genetic predispositions and environmental factors. Epigenetic modifica...
    Loading Comments...
    Show Resources
    Attendees
    • See more